Gurnet Point-backed Auregen taps Amgen vet to lead; Ex-Roche RNA chief takes CEO post at Genevant
→ Gurnet Point Capital-backed Auregen BioTherapeutics has tapped Amgen vet Richard Davies to lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
